Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-011376
Filing Date
2024-08-07
Accepted
2024-08-07 16:30:38
Documents
70
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20240630x10q.htm   iXBRL 10-Q 1758653
2 EX-10.1 acrs-20240630xex10d1.htm EX-10.1 380711
3 EX-31.1 acrs-20240630xex31d1.htm EX-31.1 15617
4 EX-31.2 acrs-20240630xex31d2.htm EX-31.2 15658
5 EX-32.1 acrs-20240630xex32d1.htm EX-32.1 9520
  Complete submission text file 0001558370-24-011376.txt   8060258

Data Files

Seq Description Document Type Size
6 EX-101.SCH acrs-20240630.xsd EX-101.SCH 40618
7 EX-101.CAL acrs-20240630_cal.xml EX-101.CAL 42158
8 EX-101.DEF acrs-20240630_def.xml EX-101.DEF 189658
9 EX-101.LAB acrs-20240630_lab.xml EX-101.LAB 419591
10 EX-101.PRE acrs-20240630_pre.xml EX-101.PRE 294978
73 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20240630x10q_htm.xml XML 1561596
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 241184317
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)